Ivosidenib is an inhibitor of isocitrate dehydrogenase 1 (IDH1) and significantly improved the progression-free survival of IDH1-mutant CC patients compared to that of the placebo arm [37]. The gene discussed is IDH1; the disease is cholangiocarcinoma.